Showing 3041-3050 of 5621 results for "".
- NIH Study Classifies Vision Loss and Retinal Changes in Stargardt Diseasehttps://modernod.com/news/nih-study-classifies-vision-loss-and-retinal-changes-in-stargardt-disease/2480590/National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt. The method quantifies disease-related loss of light-sensing retina cells, yielding information for monitoring patients, understanding genetic causes of the disea
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://modernod.com/news/researchers-define-keys-to-recognizing-ocular-rosacea/2480589/A pair of new studies help establish the relative prevalence of signs and symptoms of the eyes of rosacea patients (ocular rosacea), as well as the importance of
- Allotex Announces 3-Year Results of Allogeneic Inlays for the Treatment of Hyperopia and Presbyopiahttps://modernod.com/news/allotex-announces-3-year-results-of-allogeneic-inlays-for-the-treatment-of-hyperopia-and-presbyopia/2480575/Allotex, the maker of
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Modular Super-Enhancer Controls Retinal Developmenthttps://modernod.com/news/modular-super-enhancer-controls-retinal-development/2480571/Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer. Enhancers are regions of DNA that do not
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseaseshttps://modernod.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/The Foundation Fighting Blindness announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation. The program will provide funding for six early translational research projects over 3 years for the dev
- ImprimisRx to Assume Full Responsibility for US Sales and Marketing Activities for Dexycuhttps://modernod.com/news/imprimisrx-to-assume-full-responsibility-for-us-sales-and-marketing-activities-for-dexycu/2480499/EyePoint Pharmaceut
- New Technology, Greater Patient Awareness Will Help Drive Gains in Premium Cataract Surgeryhttps://modernod.com/news/new-technology-greater-patient-awareness-will-help-drive-gains-in-premium-cataract-surgery/2480489/Gains in the premium cataract surgery market over the next 5 years will be driven by technological improvements, growing value awareness among patients, declining reimbursement in the public
- Ophthalmic Sciences Unveils AI Contactless Device for Measuring IOPhttps://modernod.com/news/ophthalmic-sciences-unveils-ai-contactless-device-for-measuring-iop/2480487/